OBJECTIVE: To compare the incidence of venous thromboembolism (VTE) before and after the implementation of standardized extended duration prophylaxis guidelines in women undergoing laparotomy for gynecologic cancer. METHODS: In October 2009, departmental practice guidelines were implemented for VTE prevention. Patients undergoing laparotomy for gynecologic cancer were started on low molecular weight heparin (LMWH) within 24h of surgery and it was continued for a total of 28 days postoperatively. The incidence of VTE diagnosed within 30 and 90 days of surgery was determined and compared to a historic cohort of patients who underwent surgery prior to implementation of the guidelines. RESULTS: The incidence of VTE within 30 days of surgery decreased from 2.7% (8/300) to 0.6% (2/334) following implementation of VTE prevention guidelines (78% reduction, p=0.040). However, when the pre and post-guideline implementation groups were compared for the development of VTE within 90 days of surgery, there was no significant difference (11/300 (3.7%) vs. 10/334 (3.0%) respectively, p=0.619). The median time between surgery and VTE diagnosis was 12 days in the pre-guideline implementation group, compared with 57 days in the post-guideline implementation group (p=0.012). CONCLUSION: Patients receiving extended duration LMWH were found to have significantly lower rates of VTE within 30 days of surgery when compared with similar patients who did not receive extended duration LMWH. However, this effect was not sustained when the groups were compared for VTE diagnosis within 90 days of surgery. Additional study is needed to further reduce long-term VTE rates in this high-risk population.
OBJECTIVE: To compare the incidence of venous thromboembolism (VTE) before and after the implementation of standardized extended duration prophylaxis guidelines in women undergoing laparotomy for gynecologic cancer. METHODS: In October 2009, departmental practice guidelines were implemented for VTE prevention. Patients undergoing laparotomy for gynecologic cancer were started on low molecular weight heparin (LMWH) within 24h of surgery and it was continued for a total of 28 days postoperatively. The incidence of VTE diagnosed within 30 and 90 days of surgery was determined and compared to a historic cohort of patients who underwent surgery prior to implementation of the guidelines. RESULTS: The incidence of VTE within 30 days of surgery decreased from 2.7% (8/300) to 0.6% (2/334) following implementation of VTE prevention guidelines (78% reduction, p=0.040). However, when the pre and post-guideline implementation groups were compared for the development of VTE within 90 days of surgery, there was no significant difference (11/300 (3.7%) vs. 10/334 (3.0%) respectively, p=0.619). The median time between surgery and VTE diagnosis was 12 days in the pre-guideline implementation group, compared with 57 days in the post-guideline implementation group (p=0.012). CONCLUSION:Patients receiving extended duration LMWH were found to have significantly lower rates of VTE within 30 days of surgery when compared with similar patients who did not receive extended duration LMWH. However, this effect was not sustained when the groups were compared for VTE diagnosis within 90 days of surgery. Additional study is needed to further reduce long-term VTE rates in this high-risk population.
Authors: Victor F Tapson; Thomas M Hyers; Albert L Waldo; David J Ballard; Richard C Becker; Joseph A Caprini; Roger Khetan; Ann K Wittkowsky; Kevin J Colgan; Alicia C Shillington Journal: Arch Intern Med Date: 2005-07-11
Authors: David Bergqvist; Giancarlo Agnelli; Alexander T Cohen; Amiram Eldor; Paul E Nilsson; Anne Le Moigne-Amrani; Flavia Dietrich-Neto Journal: N Engl J Med Date: 2002-03-28 Impact factor: 91.245
Authors: Martin A Martino; Elana Borges; Eva Williamson; Sylvia Siegfried; Alan B Cantor; Johnathan Lancaster; William S Roberts; Mitchel S Hoffman Journal: Obstet Gynecol Date: 2006-03 Impact factor: 7.661
Authors: M A Martino; E Williamson; L Rajaram; J M Lancaster; M S Hoffman; G L Maxwell; D L Clarke-Pearson Journal: Gynecol Oncol Date: 2007-06-28 Impact factor: 5.482
Authors: Gary H Lyman; Alok A Khorana; Anna Falanga; Daniel Clarke-Pearson; Christopher Flowers; Mohammad Jahanzeb; Ajay Kakkar; Nicole M Kuderer; Mark N Levine; Howard Liebman; David Mendelson; Gary Raskob; Mark R Somerfield; Paul Thodiyil; David Trent; Charles W Francis Journal: J Clin Oncol Date: 2007-10-29 Impact factor: 44.544
Authors: M Heather Einstein; David M Kushner; Joseph P Connor; Alex A Bohl; Thomas J Best; Michael D Evans; Richard J Chappell; Ellen M Hartenbach Journal: Obstet Gynecol Date: 2008-11 Impact factor: 7.661
Authors: Lauren S Prescott; Lisa M Kidin; Rebecca L Downs; David J Cleveland; Ginger L Wilson; Mark F Munsell; Alma Y DeJesus; Katherine E Cain; Pedro T Ramirez; Michael H Kroll; Charles F Levenback; Kathleen M Schmeler Journal: Int J Gynecol Cancer Date: 2015-01 Impact factor: 3.437